Nivolumab versus nivolumab with ipilimumab versus trifluridine/tipiracil for metastatic microsatellite instability-high colorectal cancer: A modeling decision analysis

MLA

Jin G. Choi, et al. “Nivolumab versus Nivolumab with Ipilimumab versus Trifluridine/Tipiracil for Metastatic Microsatellite Instability-High Colorectal Cancer: A Modeling Decision Analysis.” Journal of Clinical Oncology, vol. 36, Feb. 2018, p. 829. EBSCOhost, https://doi.org/10.1200/jco.2018.36.4_suppl.829.

APA

Jin G. Choi, Jacqueline N. Chu, Jeffrey W. Clark, Chin Hur, Kerry L. Reynolds, Justin F. Gainor, Sassan Ostvar, Daniel C. Chung, & James A. Torchia. (2018). Nivolumab versus nivolumab with ipilimumab versus trifluridine/tipiracil for metastatic microsatellite instability-high colorectal cancer: A modeling decision analysis. Journal of Clinical Oncology, 36, 829. https://doi.org/10.1200/jco.2018.36.4_suppl.829

Chicago

Jin G. Choi, Jacqueline N. Chu, Jeffrey W. Clark, Chin Hur, Kerry L. Reynolds, Justin F. Gainor, Sassan Ostvar, Daniel C. Chung, and James A. Torchia. 2018. “Nivolumab versus Nivolumab with Ipilimumab versus Trifluridine/Tipiracil for Metastatic Microsatellite Instability-High Colorectal Cancer: A Modeling Decision Analysis.” Journal of Clinical Oncology 36 (February): 829. doi:10.1200/jco.2018.36.4_suppl.829.